IBB News and Press, iShares Biotechnology ETF From 03/25/23

2023-03-25 08:41:03 ET Summary XBI sits 58% below its all-time high. Yet I still don't think it is a good investment here. There are too many risk factors for the smaller biotech stocks this ETF owns, and tighter lending conditions will only complicate things. I rate XBI ETF a...

2023-03-24 15:01:40 ET iShares Nasdaq Biotechnology ETF ( NASDAQ: IBB ) - $0.0645 . 30-Day SEC Yield of 0.14% as of Feb. 28. Payable Mar 29; for shareholders of record Mar 24; ex-div Mar 23. For further details see: iShares Nasdaq Biotechnology ETF declares q...

2023-03-24 03:00:00 ET Summary We remain selective in taking risk as macro factors continue to drive sentiment. Despite the uncertainties, investors should not lose sight of equities’ enduring role in a well-balanced portfolio. We advocate a near-term focus on resilienc...

2023-03-23 08:56:52 ET Popular biotech exchange traded fund SPDR S&P Biotech ETF ( NYSEARCA: XBI ) dropped more than 3% on Wednesday. As a result, the ETF reached a new 8-month low. XBI touched $73.06 a share on Wednesday which marked its lowest level dating back to ...

2023-03-22 08:54:00 ET Summary Technology and healthcare are good examples of sectors that can play different equity-allocation roles than you might expect. Unlike income-oriented defensive sectors, which are sensitive to changes in interest rates, some of the highest-quality low-...

2023-03-20 11:04:21 ET Summary The unfolding banking crisis has been shaking financial markets and contributing to a negative tone in the stock market. Recession risks have risen as the crisis envelops more banks. The Federal Reserve's upcoming interest rate policy meeting is ...

2023-03-18 16:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-03-16 15:51:00 ET Summary How SVB's collapse is impacting healthcare startups. Pfizer to buy Seagen for $43B. What it means for the sector. Why healthcare startups could face funding challenges. The collapse of Silicon Valley Bank is raising concerns about fun...

2023-03-16 06:31:14 ET Summary The pharma/biotech subsector is undervalued by 16% relative to 11-year averages. Healthcare equipment is the less attractive subsector regarding both valuation and quality. Fast facts on PBE, a biotechnology and genomics ETF. 10 stocks cheape...

2023-03-14 02:00:18 ET Summary The private domestic sector balance increased by $190+ billion in February 2023 despite the external sector and bank credit creation headwinds. Bank credit retraction was -$30+ billion as more loans were repaid or written off than were created. T...